Hong Kong · Delayed Price · Currency is HKD AIM Vaccine Statistics
Total Valuation
AIM Vaccine has a market cap or net worth of HKD 2.20 billion. The enterprise value is 4.23 billion.
| Market Cap | 2.20B |
| Enterprise Value | 4.23B |
Important Dates
The next estimated earnings date is Monday, November 23, 2026.
| Earnings Date | Nov 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM Vaccine has 1.23 billion shares outstanding. The number of shares has increased by 0.86% in one year.
| Current Share Class | 507.67M |
| Shares Outstanding | 1.23B |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 23.76% |
| Owned by Institutions (%) | 2.13% |
| Float | 353.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.90 |
| PB Ratio | 0.68 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | 28.19 |
| P/OCF Ratio | 11.53 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 54.18 |
Financial Position
The company has a current ratio of 0.61, with a Debt / Equity ratio of 0.63.
| Current Ratio | 0.61 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | n/a |
| Debt / FCF | 26.17 |
| Interest Coverage | -3.19 |
Financial Efficiency
Return on equity (ROE) is -23.23% and return on invested capital (ROIC) is -4.35%.
| Return on Equity (ROE) | -23.23% |
| Return on Assets (ROA) | -1.77% |
| Return on Invested Capital (ROIC) | -4.35% |
| Return on Capital Employed (ROCE) | -5.83% |
| Weighted Average Cost of Capital (WACC) | 3.75% |
| Revenue Per Employee | 854,676 |
| Profits Per Employee | -569,272 |
| Employee Count | 1,466 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | -11.04M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.92% in the last 52 weeks. The beta is 0.09, so AIM Vaccine's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -58.92% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 2.41 |
| Relative Strength Index (RSI) | 56.18 |
| Average Volume (20 Days) | 172,480 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM Vaccine had revenue of HKD 1.16 billion and -770.22 million in losses. Loss per share was -0.63.
| Revenue | 1.16B |
| Gross Profit | 767.42M |
| Operating Income | -220.89M |
| Pretax Income | -862.50M |
| Net Income | -770.22M |
| EBITDA | -88.67M |
| EBIT | -220.89M |
| Loss Per Share | -0.63 |
Balance Sheet
The company has 210.86 million in cash and 2.04 billion in debt, with a net cash position of -1.83 billion or -1.49 per share.
| Cash & Cash Equivalents | 210.86M |
| Total Debt | 2.04B |
| Net Cash | -1.83B |
| Net Cash Per Share | -1.49 |
| Equity (Book Value) | 3.24B |
| Book Value Per Share | 2.48 |
| Working Capital | -1.39B |
Cash Flow
In the last 12 months, operating cash flow was 190.87 million and capital expenditures -112.76 million, giving a free cash flow of 78.11 million.
| Operating Cash Flow | 190.87M |
| Capital Expenditures | -112.76M |
| Depreciation & Amortization | 134.31M |
| Net Borrowing | -184.49M |
| Free Cash Flow | 78.11M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 66.36%, with operating and profit margins of -19.10% and -66.61%.
| Gross Margin | 66.36% |
| Operating Margin | -19.10% |
| Pretax Margin | -74.59% |
| Profit Margin | -66.61% |
| EBITDA Margin | -7.67% |
| EBIT Margin | -19.10% |
| FCF Margin | 6.65% |
Dividends & Yields
AIM Vaccine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | -34.98% |
| FCF Yield | 3.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AIM Vaccine has an Altman Z-Score of -0.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.11 |
| Piotroski F-Score | 3 |